English
简体中文
Total: £ 56.28
Published Date: 2024-09-13 | Pages: 140 | Tables: 261 | Pharma & Healthcare
The global market for Influenza Drugs was estimated to be worth US$ 1707.6 million in 2023 and is forecast to a readjusted size of US$ 2151.5 million by 2030 with a CAGR of 3.3% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Influenza Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Influenza Drugs by region & country, by Type, and by Application.
The Influenza Drugs market size, estimations, and forecasts are provided in terms of sales volume (K MT) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza Drugs.
Market Segmentation
By Company
Bristol-Myers Squibb]
AstraZeneca
Eli Lilly
Roche
GlaxoSmithKline
Novartis
Pfizer
Sanofi Pasteur
Bayer
Celgene
Seqirus
Protein Sciences Corporation
Serum Institute of India
Emergent Biosolutions
BioCryst Pharmaceuticals
Alvogen
Segment by Type:
Zanamivir
Oseltamivir Phosphate
Peramivir
Other Influenza Drugs
Segment by Application
Adults
Chidren
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Influenza Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Influenza Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Influenza Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Influenza Drugs Product Introduction
1.2 Global Influenza Drugs Market Size Forecast
1.2.1 Global Influenza Drugs Sales Value (2019-2030)
1.2.2 Global Influenza Drugs Sales Volume (2019-2030)
1.2.3 Global Influenza Drugs Sales Price (2019-2030)
1.3 Influenza Drugs Market Trends & Drivers
1.3.1 Influenza Drugs Industry Trends
1.3.2 Influenza Drugs Market Drivers & Opportunity
1.3.3 Influenza Drugs Market Challenges
1.3.4 Influenza Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Influenza Drugs Players Revenue Ranking (2023)
2.2 Global Influenza Drugs Revenue by Company (2019-2024)
2.3 Global Influenza Drugs Players Sales Volume Ranking (2023)
2.4 Global Influenza Drugs Sales Volume by Company Players (2019-2024)
2.5 Global Influenza Drugs Average Price by Company (2019-2024)
2.6 Key Manufacturers Influenza Drugs Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Influenza Drugs Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Influenza Drugs
2.9 Influenza Drugs Market Competitive Analysis
2.9.1 Influenza Drugs Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Influenza Drugs Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Drugs as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Zanamivir
3.1.2 Oseltamivir Phosphate
3.1.3 Peramivir
3.1.4 Other Influenza Drugs
3.2 Global Influenza Drugs Sales Value by Type
3.2.1 Global Influenza Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Influenza Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Influenza Drugs Sales Value, by Type (%) (2019-2030)
3.3 Global Influenza Drugs Sales Volume by Type
3.3.1 Global Influenza Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Influenza Drugs Sales Volume, by Type (2019-2030)
3.3.3 Global Influenza Drugs Sales Volume, by Type (%) (2019-2030)
3.4 Global Influenza Drugs Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Adults
4.1.2 Chidren
4.2 Global Influenza Drugs Sales Value by Application
4.2.1 Global Influenza Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Influenza Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Influenza Drugs Sales Value, by Application (%) (2019-2030)
4.3 Global Influenza Drugs Sales Volume by Application
4.3.1 Global Influenza Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Influenza Drugs Sales Volume, by Application (2019-2030)
4.3.3 Global Influenza Drugs Sales Volume, by Application (%) (2019-2030)
4.4 Global Influenza Drugs Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Influenza Drugs Sales Value by Region
5.1.1 Global Influenza Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Influenza Drugs Sales Value by Region (2019-2024)
5.1.3 Global Influenza Drugs Sales Value by Region (2025-2030)
5.1.4 Global Influenza Drugs Sales Value by Region (%), (2019-2030)
5.2 Global Influenza Drugs Sales Volume by Region
5.2.1 Global Influenza Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Influenza Drugs Sales Volume by Region (2019-2024)
5.2.3 Global Influenza Drugs Sales Volume by Region (2025-2030)
5.2.4 Global Influenza Drugs Sales Volume by Region (%), (2019-2030)
5.3 Global Influenza Drugs Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Influenza Drugs Sales Value, 2019-2030
5.4.2 North America Influenza Drugs Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Influenza Drugs Sales Value, 2019-2030
5.5.2 Europe Influenza Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Influenza Drugs Sales Value, 2019-2030
5.6.2 Asia Pacific Influenza Drugs Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Influenza Drugs Sales Value, 2019-2030
5.7.2 South America Influenza Drugs Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Influenza Drugs Sales Value, 2019-2030
5.8.2 Middle East & Africa Influenza Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Influenza Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Influenza Drugs Sales Value
6.2.1 Key Countries/Regions Influenza Drugs Sales Value, 2019-2030
6.2.2 Key Countries/Regions Influenza Drugs Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Influenza Drugs Sales Value, 2019-2030
6.3.2 United States Influenza Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Influenza Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Influenza Drugs Sales Value, 2019-2030
6.4.2 Europe Influenza Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Influenza Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Influenza Drugs Sales Value, 2019-2030
6.5.2 China Influenza Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Influenza Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Influenza Drugs Sales Value, 2019-2030
6.6.2 Japan Influenza Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Influenza Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Influenza Drugs Sales Value, 2019-2030
6.7.2 South Korea Influenza Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Influenza Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Influenza Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Influenza Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Influenza Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Influenza Drugs Sales Value, 2019-2030
6.9.2 India Influenza Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Influenza Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bristol-Myers Squibb]
7.1.1 Bristol-Myers Squibb] Company Information
7.1.2 Bristol-Myers Squibb] Introduction and Business Overview
7.1.3 Bristol-Myers Squibb] Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Bristol-Myers Squibb] Influenza Drugs Product Offerings
7.1.5 Bristol-Myers Squibb] Recent Development
7.2 AstraZeneca
7.2.1 AstraZeneca Company Information
7.2.2 AstraZeneca Introduction and Business Overview
7.2.3 AstraZeneca Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.2.4 AstraZeneca Influenza Drugs Product Offerings
7.2.5 AstraZeneca Recent Development
7.3 Eli Lilly
7.3.1 Eli Lilly Company Information
7.3.2 Eli Lilly Introduction and Business Overview
7.3.3 Eli Lilly Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Eli Lilly Influenza Drugs Product Offerings
7.3.5 Eli Lilly Recent Development
7.4 Roche
7.4.1 Roche Company Information
7.4.2 Roche Introduction and Business Overview
7.4.3 Roche Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Roche Influenza Drugs Product Offerings
7.4.5 Roche Recent Development
7.5 GlaxoSmithKline
7.5.1 GlaxoSmithKline Company Information
7.5.2 GlaxoSmithKline Introduction and Business Overview
7.5.3 GlaxoSmithKline Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.5.4 GlaxoSmithKline Influenza Drugs Product Offerings
7.5.5 GlaxoSmithKline Recent Development
7.6 Novartis
7.6.1 Novartis Company Information
7.6.2 Novartis Introduction and Business Overview
7.6.3 Novartis Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Novartis Influenza Drugs Product Offerings
7.6.5 Novartis Recent Development
7.7 Pfizer
7.7.1 Pfizer Company Information
7.7.2 Pfizer Introduction and Business Overview
7.7.3 Pfizer Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Pfizer Influenza Drugs Product Offerings
7.7.5 Pfizer Recent Development
7.8 Sanofi Pasteur
7.8.1 Sanofi Pasteur Company Information
7.8.2 Sanofi Pasteur Introduction and Business Overview
7.8.3 Sanofi Pasteur Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Sanofi Pasteur Influenza Drugs Product Offerings
7.8.5 Sanofi Pasteur Recent Development
7.9 Bayer
7.9.1 Bayer Company Information
7.9.2 Bayer Introduction and Business Overview
7.9.3 Bayer Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Bayer Influenza Drugs Product Offerings
7.9.5 Bayer Recent Development
7.10 Celgene
7.10.1 Celgene Company Information
7.10.2 Celgene Introduction and Business Overview
7.10.3 Celgene Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Celgene Influenza Drugs Product Offerings
7.10.5 Celgene Recent Development
7.11 Seqirus
7.11.1 Seqirus Company Information
7.11.2 Seqirus Introduction and Business Overview
7.11.3 Seqirus Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Seqirus Influenza Drugs Product Offerings
7.11.5 Seqirus Recent Development
7.12 Protein Sciences Corporation
7.12.1 Protein Sciences Corporation Company Information
7.12.2 Protein Sciences Corporation Introduction and Business Overview
7.12.3 Protein Sciences Corporation Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Protein Sciences Corporation Influenza Drugs Product Offerings
7.12.5 Protein Sciences Corporation Recent Development
7.13 Serum Institute of India
7.13.1 Serum Institute of India Company Information
7.13.2 Serum Institute of India Introduction and Business Overview
7.13.3 Serum Institute of India Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Serum Institute of India Influenza Drugs Product Offerings
7.13.5 Serum Institute of India Recent Development
7.14 Emergent Biosolutions
7.14.1 Emergent Biosolutions Company Information
7.14.2 Emergent Biosolutions Introduction and Business Overview
7.14.3 Emergent Biosolutions Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Emergent Biosolutions Influenza Drugs Product Offerings
7.14.5 Emergent Biosolutions Recent Development
7.15 BioCryst Pharmaceuticals
7.15.1 BioCryst Pharmaceuticals Company Information
7.15.2 BioCryst Pharmaceuticals Introduction and Business Overview
7.15.3 BioCryst Pharmaceuticals Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.15.4 BioCryst Pharmaceuticals Influenza Drugs Product Offerings
7.15.5 BioCryst Pharmaceuticals Recent Development
7.16 Alvogen
7.16.1 Alvogen Company Information
7.16.2 Alvogen Introduction and Business Overview
7.16.3 Alvogen Influenza Drugs Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Alvogen Influenza Drugs Product Offerings
7.16.5 Alvogen Recent Development
8 Industry Chain Analysis
8.1 Influenza Drugs Industrial Chain
8.2 Influenza Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Influenza Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Influenza Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Influenza Drugs Market Trends
Table 2. Influenza Drugs Market Drivers & Opportunity
Table 3. Influenza Drugs Market Challenges
Table 4. Influenza Drugs Market Restraints
Table 5. Global Influenza Drugs Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Influenza Drugs Revenue Market Share by Company (2019-2024)
Table 7. Global Influenza Drugs Sales Volume by Company (2019-2024) & (K MT)
Table 8. Global Influenza Drugs Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Influenza Drugs Price by Company (2019-2024) & (USD/MT)
Table 10. Key Manufacturers Influenza Drugs Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Influenza Drugs Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Influenza Drugs
Table 13. Global Influenza Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Drugs as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Influenza Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Influenza Drugs Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Influenza Drugs Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Influenza Drugs Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Influenza Drugs Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Influenza Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K MT)
Table 22. Global Influenza Drugs Sales Volume by Type (2019-2024) & (K MT)
Table 23. Global Influenza Drugs Sales Volume by Type (2025-2030) & (K MT)
Table 24. Global Influenza Drugs Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Influenza Drugs Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Influenza Drugs Price by Type (2019-2024) & (USD/MT)
Table 27. Global Influenza Drugs Price by Type (2025-2030) & (USD/MT)
Table 28. Global Influenza Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Influenza Drugs Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Influenza Drugs Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Influenza Drugs Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Influenza Drugs Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Influenza Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K MT)
Table 34. Global Influenza Drugs Sales Volume by Application (2019-2024) & (K MT)
Table 35. Global Influenza Drugs Sales Volume by Application (2025-2030) & (K MT)
Table 36. Global Influenza Drugs Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Influenza Drugs Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Influenza Drugs Price by Application (2019-2024) & (USD/MT)
Table 39. Global Influenza Drugs Price by Application (2025-2030) & (USD/MT)
Table 40. Global Influenza Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Influenza Drugs Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Influenza Drugs Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Influenza Drugs Sales Value by Region (2019-2024) & (%)
Table 44. Global Influenza Drugs Sales Value by Region (2025-2030) & (%)
Table 45. Global Influenza Drugs Sales Volume by Region (K MT): 2019 VS 2023 VS 2030
Table 46. Global Influenza Drugs Sales Volume by Region (2019-2024) & (K MT)
Table 47. Global Influenza Drugs Sales Volume by Region (2025-2030) & (K MT)
Table 48. Global Influenza Drugs Sales Volume by Region (2019-2024) & (%)
Table 49. Global Influenza Drugs Sales Volume by Region (2025-2030) & (%)
Table 50. Global Influenza Drugs Average Price by Region (2019-2024) & (USD/MT)
Table 51. Global Influenza Drugs Average Price by Region (2025-2030) & (USD/MT)
Table 52. Key Countries/Regions Influenza Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Influenza Drugs Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Influenza Drugs Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Influenza Drugs Sales Volume, (2019-2024) & (K MT)
Table 56. Key Countries/Regions Influenza Drugs Sales Volume, (2025-2030) & (K MT)
Table 57. Bristol-Myers Squibb] Company Information
Table 58. Bristol-Myers Squibb] Introduction and Business Overview
Table 59. Bristol-Myers Squibb] Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 60. Bristol-Myers Squibb] Influenza Drugs Product Offerings
Table 61. Bristol-Myers Squibb] Recent Development
Table 62. AstraZeneca Company Information
Table 63. AstraZeneca Introduction and Business Overview
Table 64. AstraZeneca Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 65. AstraZeneca Influenza Drugs Product Offerings
Table 66. AstraZeneca Recent Development
Table 67. Eli Lilly Company Information
Table 68. Eli Lilly Introduction and Business Overview
Table 69. Eli Lilly Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 70. Eli Lilly Influenza Drugs Product Offerings
Table 71. Eli Lilly Recent Development
Table 72. Roche Company Information
Table 73. Roche Introduction and Business Overview
Table 74. Roche Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 75. Roche Influenza Drugs Product Offerings
Table 76. Roche Recent Development
Table 77. GlaxoSmithKline Company Information
Table 78. GlaxoSmithKline Introduction and Business Overview
Table 79. GlaxoSmithKline Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 80. GlaxoSmithKline Influenza Drugs Product Offerings
Table 81. GlaxoSmithKline Recent Development
Table 82. Novartis Company Information
Table 83. Novartis Introduction and Business Overview
Table 84. Novartis Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 85. Novartis Influenza Drugs Product Offerings
Table 86. Novartis Recent Development
Table 87. Pfizer Company Information
Table 88. Pfizer Introduction and Business Overview
Table 89. Pfizer Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 90. Pfizer Influenza Drugs Product Offerings
Table 91. Pfizer Recent Development
Table 92. Sanofi Pasteur Company Information
Table 93. Sanofi Pasteur Introduction and Business Overview
Table 94. Sanofi Pasteur Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 95. Sanofi Pasteur Influenza Drugs Product Offerings
Table 96. Sanofi Pasteur Recent Development
Table 97. Bayer Company Information
Table 98. Bayer Introduction and Business Overview
Table 99. Bayer Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 100. Bayer Influenza Drugs Product Offerings
Table 101. Bayer Recent Development
Table 102. Celgene Company Information
Table 103. Celgene Introduction and Business Overview
Table 104. Celgene Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 105. Celgene Influenza Drugs Product Offerings
Table 106. Celgene Recent Development
Table 107. Seqirus Company Information
Table 108. Seqirus Introduction and Business Overview
Table 109. Seqirus Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 110. Seqirus Influenza Drugs Product Offerings
Table 111. Seqirus Recent Development
Table 112. Protein Sciences Corporation Company Information
Table 113. Protein Sciences Corporation Introduction and Business Overview
Table 114. Protein Sciences Corporation Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 115. Protein Sciences Corporation Influenza Drugs Product Offerings
Table 116. Protein Sciences Corporation Recent Development
Table 117. Serum Institute of India Company Information
Table 118. Serum Institute of India Introduction and Business Overview
Table 119. Serum Institute of India Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 120. Serum Institute of India Influenza Drugs Product Offerings
Table 121. Serum Institute of India Recent Development
Table 122. Emergent Biosolutions Company Information
Table 123. Emergent Biosolutions Introduction and Business Overview
Table 124. Emergent Biosolutions Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 125. Emergent Biosolutions Influenza Drugs Product Offerings
Table 126. Emergent Biosolutions Recent Development
Table 127. BioCryst Pharmaceuticals Company Information
Table 128. BioCryst Pharmaceuticals Introduction and Business Overview
Table 129. BioCryst Pharmaceuticals Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 130. BioCryst Pharmaceuticals Influenza Drugs Product Offerings
Table 131. BioCryst Pharmaceuticals Recent Development
Table 132. Alvogen Company Information
Table 133. Alvogen Introduction and Business Overview
Table 134. Alvogen Influenza Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 135. Alvogen Influenza Drugs Product Offerings
Table 136. Alvogen Recent Development
Table 137. Key Raw Materials Lists
Table 138. Raw Materials Key Suppliers Lists
Table 139. Influenza Drugs Downstream Customers
Table 140. Influenza Drugs Distributors List
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Influenza Drugs Product Picture
Figure 2. Global Influenza Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Influenza Drugs Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Influenza Drugs Sales Volume (2019-2030) & (K MT)
Figure 5. Global Influenza Drugs Sales Price (2019-2030) & (USD/MT)
Figure 6. Influenza Drugs Report Years Considered
Figure 7. Global Influenza Drugs Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Influenza Drugs Players Sales Volume Ranking (2023) & (K MT)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Influenza Drugs Revenue in 2023
Figure 10. Influenza Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Zanamivir Picture
Figure 12. Oseltamivir Phosphate Picture
Figure 13. Peramivir Picture
Figure 14. Other Influenza Drugs Picture
Figure 15. Global Influenza Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Influenza Drugs Sales Value Market Share by Type, 2023 & 2030
Figure 17. Global Influenza Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K MT)
Figure 18. Global Influenza Drugs Sales Volume Market Share by Type, 2023 & 2030
Figure 19. Global Influenza Drugs Price by Type (2019-2030) & (USD/MT)
Figure 20. Product Picture of Adults
Figure 21. Product Picture of Chidren
Figure 22. Global Influenza Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 23. Global Influenza Drugs Sales Value Market Share by Application, 2023 & 2030
Figure 24. Global Influenza Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K MT)
Figure 25. Global Influenza Drugs Sales Volume Market Share by Application, 2023 & 2030
Figure 26. Global Influenza Drugs Price by Application (2019-2030) & (USD/MT)
Figure 27. North America Influenza Drugs Sales Value (2019-2030) & (US$ Million)
Figure 28. North America Influenza Drugs Sales Value by Country (%), 2023 VS 2030
Figure 29. Europe Influenza Drugs Sales Value (2019-2030) & (US$ Million)
Figure 30. Europe Influenza Drugs Sales Value by Country (%), 2023 VS 2030
Figure 31. Asia Pacific Influenza Drugs Sales Value (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Influenza Drugs Sales Value by Country (%), 2023 VS 2030
Figure 33. South America Influenza Drugs Sales Value (2019-2030) & (US$ Million)
Figure 34. South America Influenza Drugs Sales Value by Country (%), 2023 VS 2030
Figure 35. Middle East & Africa Influenza Drugs Sales Value (2019-2030) & (US$ Million)
Figure 36. Middle East & Africa Influenza Drugs Sales Value by Country (%), 2023 VS 2030
Figure 37. Key Countries/Regions Influenza Drugs Sales Value (%), (2019-2030)
Figure 38. Key Countries/Regions Influenza Drugs Sales Volume (%), (2019-2030)
Figure 39. United States Influenza Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 40. United States Influenza Drugs Sales Value by Type (%), 2023 VS 2030
Figure 41. United States Influenza Drugs Sales Value by Application (%), 2023 VS 2030
Figure 42. Europe Influenza Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 43. Europe Influenza Drugs Sales Value by Type (%), 2023 VS 2030
Figure 44. Europe Influenza Drugs Sales Value by Application (%), 2023 VS 2030
Figure 45. China Influenza Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 46. China Influenza Drugs Sales Value by Type (%), 2023 VS 2030
Figure 47. China Influenza Drugs Sales Value by Application (%), 2023 VS 2030
Figure 48. Japan Influenza Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 49. Japan Influenza Drugs Sales Value by Type (%), 2023 VS 2030
Figure 50. Japan Influenza Drugs Sales Value by Application (%), 2023 VS 2030
Figure 51. South Korea Influenza Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 52. South Korea Influenza Drugs Sales Value by Type (%), 2023 VS 2030
Figure 53. South Korea Influenza Drugs Sales Value by Application (%), 2023 VS 2030
Figure 54. Southeast Asia Influenza Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 55. Southeast Asia Influenza Drugs Sales Value by Type (%), 2023 VS 2030
Figure 56. Southeast Asia Influenza Drugs Sales Value by Application (%), 2023 VS 2030
Figure 57. India Influenza Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 58. India Influenza Drugs Sales Value by Type (%), 2023 VS 2030
Figure 59. India Influenza Drugs Sales Value by Application (%), 2023 VS 2030
Figure 60. Influenza Drugs Industrial Chain
Figure 61. Influenza Drugs Manufacturing Cost Structure
Figure 62. Channels of Distribution (Direct Sales, and Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
